Zoetis Announces First Quarter 2024 Results
PARSIPPANY, N.J. & TEANECK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.
Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results
Zoetis to Participate in the Barclays Global Healthcare Conference
Zoetis to Participate in Bank of America Securities 2024 Animal Health Summit
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world's leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health.
Zoetis Declares Second Quarter 2024 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call.
Zoetis Announces Third Quarter 2023 Results
Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference